Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | Chief Development Officer | September 01, 2026 | September 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORCEPT THERAPEUTICS INC
Report date September 01, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,313 |
Last balance in matching sequence
After 2026-09-01 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-09-01 · Grant · Acquired 164 · Balance 4,149 F1: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026. F2: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Row 2 · 2026-09-01 · Grant · Acquired 164 · Balance 4,313 F4: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026.
F2: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
F3: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F4: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 17, 2025 Filed Dec 4, 2025 01:08 UTC Amendment | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 5,287 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-307194 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was inadvertently omitted from previous filings. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 22:10 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $21.65 | $0.00 |
DisclosureSEC source: 0001193125-25-272572 · ownership.xml · derivative · entry 5 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 290,000 Underlying: Common Stock · 20,000 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 22:10 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 300 | $76.28 | $22,884.00 |
DisclosureSEC source: 0001193125-25-272572 · ownership.xml · nonDerivative · entry 4 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,287 F1 · kind: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 22:10 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 13,164 | $75.64 | $995,678.89 |
DisclosureSEC source: 0001193125-25-272572 · ownership.xml · nonDerivative · entry 3 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,587 F1 · kind: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $75.185 to $76.17 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 22:10 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 6,536 | $74.75 | $488,558.81 |
DisclosureSEC source: 0001193125-25-272572 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,751 F1 · kind: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $74.17 to $75.165 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 22:10 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 20,000 | $21.65 | $433,000.00 |
DisclosureSEC source: 0001193125-25-272572 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,287 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 07, 2025 Filed Oct 9, 2025 21:51 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $21.65 | $0.00 |
DisclosureSEC source: 0001193125-25-236107 · ownership.xml · derivative · entry 3 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 310,000 Underlying: Common Stock · 20,000 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| October 07, 2025 Filed Oct 9, 2025 21:51 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 20,000 | $89.94 | $1,798,782.00 |
DisclosureSEC source: 0001193125-25-236107 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,287 F1 · kind: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $89.85 to $90.18 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| October 07, 2025 Filed Oct 9, 2025 21:51 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 20,000 | $21.65 | $433,000.00 |
DisclosureSEC source: 0001193125-25-236107 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,287 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 19, 2025 Filed Sep 23, 2025 21:06 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 200 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-213559 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,287 F1 · kind: Represents a donation by the Reporting Person to Fidelity Charitable Giving Account. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 23:59 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $21.65 | $0.00 |
DisclosureSEC source: 0001193125-25-196319 · ownership.xml · derivative · entry 4 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 330,000 Underlying: Common Stock · 20,000 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 23:59 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 4,406 | $70.85 | $312,155.41 |
DisclosureSEC source: 0001193125-25-196319 · ownership.xml · nonDerivative · entry 3 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,487 F1 · kind: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $70.725 to $71.08 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 23:59 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 15,594 | $70.39 | $1,097,692.85 |
DisclosureSEC source: 0001193125-25-196319 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,893 F1 · kind: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $69.725 to $70.72 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 23:59 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 20,000 | $21.65 | $433,000.00 |
DisclosureSEC source: 0001193125-25-196319 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,487 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 23:19 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 35,007 | $0.00 Strike: $21.65 | $0.00 |
DisclosureSEC source: 0001193125-25-179180 · ownership.xml · derivative · entry 3 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 35,007 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 23:19 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 35,007 | $71.77 | $2,512,452.39 |
DisclosureSEC source: 0001193125-25-179180 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,487 F1 · kind: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 23:19 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 35,007 | $21.65 | $757,901.55 |
DisclosureSEC source: 0001193125-25-179180 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,494 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2025 Filed Aug 7, 2025 23:17 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 14 | $0.00 Strike: $21.65 | $0.00 |
DisclosureSEC source: 0000950170-25-105330 · ownership.xml · derivative · entry 3 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 385,007 Underlying: Common Stock · 14 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 05, 2025 Filed Aug 7, 2025 23:17 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 14 | $71.77 | $1,004.78 |
DisclosureSEC source: 0000950170-25-105330 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,487 F1 · kind: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. Read SEC document |
| August 05, 2025 Filed Aug 7, 2025 23:17 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 14 | $21.65 | $303.10 |
DisclosureSEC source: 0000950170-25-105330 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 18, 2025 Filed Jul 21, 2025 23:10 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 500 | $0.00 Strike: $21.65 | $0.00 |
DisclosureSEC source: 0000950170-25-097370 · ownership.xml · derivative · entry 6 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 385,021 Underlying: Common Stock · 500 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 18, 2025 Filed Jul 21, 2025 23:10 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 500 | $73.44 | $36,721.00 |
DisclosureSEC source: 0000950170-25-097370 · ownership.xml · nonDerivative · entry 4 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,487 F1 · kind: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.40 to $73.47 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| July 18, 2025 Filed Jul 21, 2025 23:10 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 500 | $21.65 | $10,825.00 |
DisclosureSEC source: 0000950170-25-097370 · ownership.xml · nonDerivative · entry 3 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,987 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 17, 2025 Filed Jul 21, 2025 23:10 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 4,379 | $0.00 Strike: $21.65 | $0.00 |
DisclosureSEC source: 0000950170-25-097370 · ownership.xml · derivative · entry 5 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 385,521 Underlying: Common Stock · 4,379 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 17, 2025 Filed Jul 21, 2025 23:10 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 4,379 | $73.48 | $321,773.74 |
DisclosureSEC source: 0000950170-25-097370 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,487 F1 · kind: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.40 to $73.74 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| July 17, 2025 Filed Jul 21, 2025 23:10 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 4,379 | $21.65 | $94,805.35 |
DisclosureSEC source: 0000950170-25-097370 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,866 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2025 Filed Jul 4, 2025 00:39 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 100 | $0.00 Strike: $21.65 | $0.00 |
DisclosureSEC source: 0000950170-25-094123 · ownership.xml · derivative · entry 3 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 389,900 Underlying: Common Stock · 100 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 01, 2025 Filed Jul 4, 2025 00:39 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 100 | $73.51 | $7,350.50 |
DisclosureSEC source: 0000950170-25-094123 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,487 F1 · kind: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. Read SEC document |
| July 01, 2025 Filed Jul 4, 2025 00:39 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 100 | $21.65 | $2,165.00 |
DisclosureSEC source: 0000950170-25-094123 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,587 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 00:41 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $21.65 | $0.00 |
DisclosureSEC source: 0000950170-25-085755 · ownership.xml · derivative · entry 4 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 390,000 Underlying: Common Stock · 20,000 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 00:41 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 3,082 | $72.75 | $224,213.65 |
DisclosureSEC source: 0000950170-25-085755 · ownership.xml · nonDerivative · entry 3 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,487 F1 · kind: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $72.70 to $72.97 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 00:41 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 16,918 | $72.36 | $1,224,260.92 |
DisclosureSEC source: 0000950170-25-085755 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,569 F1 · kind: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $71.70 to $72.695 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 00:41 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 20,000 | $21.65 | $433,000.00 |
DisclosureSEC source: 0000950170-25-085755 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,487 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 16, 2025 Filed May 20, 2025 23:35 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 32,262 | $0.00 Strike: $21.65 | $0.00 |
DisclosureSEC source: 0000950170-25-075484 · ownership.xml · derivative · entry 3 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 32,262 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 16, 2025 Filed May 20, 2025 23:35 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 32,262 | $74.17 | $2,393,014.49 |
DisclosureSEC source: 0000950170-25-075484 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,487 F1 · kind: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.94 to $74.66 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| May 16, 2025 Filed May 20, 2025 23:35 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 32,262 | $21.65 | $698,472.30 |
DisclosureSEC source: 0000950170-25-075484 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,749 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2025 Filed May 9, 2025 00:20 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 7,060 | $0.00 Strike: $21.65 | $0.00 |
DisclosureSEC source: 0000950170-25-067451 · ownership.xml · derivative · entry 3 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 442,262 Underlying: Common Stock · 7,060 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 06, 2025 Filed May 9, 2025 00:20 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 7,060 | $74.31 | $524,652.60 |
DisclosureSEC source: 0000950170-25-067451 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,487 F1 · kind: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. Read SEC document |
| May 06, 2025 Filed May 9, 2025 00:20 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 7,060 | $21.65 | $152,849.00 |
DisclosureSEC source: 0000950170-25-067451 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 00:08 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 678 | $0.00 Strike: $21.65 | $0.00 |
DisclosureSEC source: 0000950170-25-049800 · ownership.xml · derivative · entry 3 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 449,322 Underlying: Common Stock · 678 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 00:08 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 678 | $114.51 | $77,639.00 |
DisclosureSEC source: 0000950170-25-049800 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,487 F1 · kind: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.29 to $114.71 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 00:08 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 678 | $21.65 | $14,678.70 |
DisclosureSEC source: 0000950170-25-049800 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 00:53 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $19.26 | $0.00 |
DisclosureSEC source: 0000950170-25-032747 · ownership.xml · derivative · entry 4 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 20,000 shares Expires 2032-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 00:53 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 20,000 | $59.07 | $1,181,400.00 |
DisclosureSEC source: 0000950170-25-032747 · ownership.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,487 F1 · kind: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 00:53 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 20,000 | $19.26 | $385,200.00 |
DisclosureSEC source: 0000950170-25-032747 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,487 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 00:53 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock option (right to buy) · Derivative | 140,000 | $0.00 Strike: $60.58 | $0.00 |
DisclosureSEC source: 0000950170-25-032747 · ownership.xml · derivative · entry 3 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2035-02-28 F2 · derivative.exercise_date: Exercise ratably in equal installments on each monthly anniversary of February 28, 2025 over a four-year period subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| December 02, 2024 Filed Dec 5, 2024 01:02 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 309 | $57.68 | $17,823.12 |
DisclosureSEC source: 0000950170-24-133448 · ownership.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,487 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. F2 · price: The closing price on November 29, 2024 was used to calculate the withholding obligation. Read SEC document |
| November 04, 2024 Filed Nov 6, 2024 00:48 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 3,394 | $0.00 Strike: $21.65 | $0.00 |
DisclosureSEC source: 0000950170-24-121742 · ownership.xml · derivative · entry 6 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 3,394 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Shares subject to the stock option vested and became exercisable with respect to 25% of the shares on the first anniversary of August 16, 2021 (the "Vesting Commencement Date") with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service. Read SEC document |
| November 04, 2024 Filed Nov 6, 2024 00:48 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 3,394 | $48.97 | $166,204.18 |
DisclosureSEC source: 0000950170-24-121742 · ownership.xml · nonDerivative · entry 4 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,796 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. F1 · balance_after: Includes 609 shares underlying unvested restricted stock units granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| November 04, 2024 Filed Nov 6, 2024 00:48 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 3,394 | $21.65 | $73,480.10 |
DisclosureSEC source: 0000950170-24-121742 · ownership.xml · nonDerivative · entry 3 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,190 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 609 shares underlying unvested restricted stock units granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.